Abiopharma

(80% Positive) Personalis, Inc. (PSNL) Provides Update on results for breast cancer surveillance

InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation

EPAM Systems, Inc. - EPAM and Cursor Announce Strategic Partnership to Build and Scale AI-Native Teams for Global Enterprises

MannKind Provides Business Updates and 2026 Growth Drivers

CorMedix Therapeutics Announces Leadership and Board Updates

Guardant Health’s Shield Blood Test for Colorectal Cancer Screening Now Available for U.S. Military Members and Families

BioVie Inc. - BioVie Completes Enrollment in Phase 2 SUNRISE-PD Trial in Early Parkinson’s Disease

Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of Americas Most Successful Small-Cap Companies

CoyaTherapeutics - Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients

Halozyme - Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab withENHANZE®

(90% Positive) GRI BIO, INC. (GRI) Provides Update on modulators for Idiopathic Pulmonary Fibrosis

Ecolab Inc. - Ecolab Earns Double ‘A’ Rating from CDP for Leadership in Water and Climate Performance

(90% Positive) MOONLAKE IMMUNOTHERAPEUTICS (MLTX) Provides Update on opportunities for inflammat

Reviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in Schizophrenia

GRI Bio Announces Additional Positive Data from Phase 2a Study in Idiopathic Pulmonary Fibrosis, Strengthening Clinical Proof-of-Concept for GRI-0621